How to Select a CTMS: Buyer's Guide

Selecting a Clinical Trial Management System (CTMS) is a multi-year commitment, not a software purchase to revisit annually. A CTMS becomes the system of record for protocols, subjects, visits, budgets, and regulatory documents across an institution’s entire trial portfolio, and switching platforms later means migrating years of operational data. This guide walks through what a CTMS actually needs to do, the evaluation criteria that separate a good institutional fit from a poor one, and the major categories of platforms on the market today — without assigning specific prices, since vendor pricing is negotiated, tiered, and changes too often to state reliably in an evergreen guide.

For a definitional overview of what a CTMS is and how it differs from adjacent systems, see Clinical Trial Management System (CTMS): What It Is and Does. For how CTMS fits alongside EDC, eTMF, RTSM, and RBM in the broader clinical trial technology stack, see Clinical Data Management Tools. This guide assumes that context and focuses specifically on the selection and procurement decision facing a research institution, hospital, or academic medical center (AMC) evaluating a CTMS for its own use — not on sponsor-side vendor oversight, which is covered separately in Clinical Trial Vendor Management.

What a CTMS Needs to Do, in Selection Terms

Every CTMS evaluation should test candidate platforms against four core functional areas, regardless of institution size:

Subject and protocol tracking — enrollment status, eligibility screening logs, subject-level visit history, and protocol amendment tracking across the trial’s full lifecycle from activation to closeout.
Visit and calendar scheduling — the protocol calendar (procedures, visit windows, standard-of-care vs. research-billable events) that drives both subject scheduling and the billing-compliance workflows described below.
Regulatory and essential-document management — IRB approvals and continuing review dates, informed consent versions, delegation-of-authority logs, and (in many institutional deployments) a built-in or integrated electronic Trial Master File (eTMF) module or interface.
Financial and budget tracking — per-subject and per-visit budgets, milestone invoicing to sponsors, and reconciliation against actual billed activity. For institutions billing federally-funded or industry-sponsored trials through a clinical billing system, this is frequently the single most consequential functional area, since it is what supports Medicare Coverage Analysis and research-billing compliance (see Medicare Coverage Analysis for Clinical Trials).

A platform that handles subject tracking and scheduling well but treats financial tracking as an afterthought (or vice versa) is a common failure pattern in CTMS selection — test all four areas with real institutional data during any evaluation, not just the modules a demo emphasizes.

Key Evaluation Criteria

Integration with EDC, eTMF, and RTSM

A CTMS rarely operates as a standalone system. It needs to exchange data — at minimum, subject IDs, visit status, and site-activation dates — with the Electronic Data Capture (EDC) system used for clinical data collection, the eTMF used for document management, and, for randomized trials, the RTSM (Randomization and Trial Supply Management) system. Ask vendors specifically about:

Whether integration is via a documented API, a pre-built connector to specific EDC/eTMF products, or requires custom middleware and professional-services work.
Whether the vendor’s own eTMF or EDC module (where offered) is optional or mandatory to unlock certain CTMS features — a common vendor lock-in pattern.
How the institution’s electronic health record (EHR) fits in, if research billing or pre-screening workflows are expected to pull from it. Some institutional CTMS deployments integrate with the EHR for subject identification and billing charge review; this is a substantially heavier integration than an EDC/eTMF connector and should be scoped explicitly, not assumed.

Single-Site vs. Multi-Site and Academic Medical Center Needs

Institution size and structure change what “good” looks like:

Single-site or small programs generally need less configurability and fewer role-based permission tiers, and are more sensitive to per-user or per-study licensing costs relative to trial volume.
Multi-site academic medical centers and health systems need role-based access control across departments, centralized reporting that rolls up across sites while preserving department-level budget ownership, and the ability to model a study that spans multiple IRBs (or a single IRB of record under a single IRB (sIRB) arrangement). See Study Start-Up in Clinical Trials for how multi-site activation sequencing depends on this.
Consortia and networks (e.g., a Clinical and Translational Science Award hub coordinating trials across affiliated hospitals) need multi-tenant or federated deployment models where individual institutions retain their own data governance while still supporting network-level reporting.

A platform sized correctly for a single-site community hospital research office is frequently the wrong fit for a large AMC, and the reverse is equally true — an enterprise platform built for a large multi-site portfolio can be more configuration overhead than a small program needs. Match the evaluation to actual trial volume and organizational structure, not aspirational scale.

Cloud (SaaS) vs. On-Premise Deployment

Most current-generation CTMS platforms are offered as cloud/SaaS deployments, and the market has moved decisively in that direction over the past decade; on-premise deployment is now the exception rather than the default for new implementations. Considerations that still matter when comparing deployment models:

IT and validation burden: on-premise deployment shifts server maintenance, backup, and infrastructure-level security controls onto the institution’s own IT function, alongside the validation obligations below. SaaS shifts most of that to the vendor, but the institution remains responsible for verifying the vendor’s controls are adequate — deployment model does not change who is ultimately accountable for data integrity.
Data residency and security review: institutional information security offices typically require a formal security review (SOC 2 report, penetration test summary, data-hosting location) before approving any cloud CTMS, and this review timeline should be built into the selection schedule — it routinely takes longer than the vendor evaluation itself.
Uptime and access during outages: ask vendors directly about their SLA, planned-maintenance windows, and what happens to in-progress work (e.g., a coordinator mid-visit-entry) during an outage.

Validation and 21 CFR Part 11 Compliance

Because a CTMS creates and stores electronic records relied on for trial conduct and, in many institutional contexts, financial and regulatory reporting, it falls within the scope of considerations under 21 CFR Part 11 — FDA’s electronic records/electronic signatures regulation — for FDA-regulated trials. In practice, this means an institution should evaluate:

Whether the vendor can supply validation documentation — an Installation Qualification/Operational Qualification (IQ/OQ) package, and evidence the vendor maintains a validated state across software updates — versus leaving the full validation burden to the purchasing institution.
Audit trail completeness: who changed what, when, and (for Part 11 purposes) with an attributable, time-stamped, non-editable record of the change.
Access controls and electronic signature support, including role-based permissions and unique user authentication that supports the identity and non-repudiation requirements electronic signatures are held to under Part 11.
Change control for vendor-pushed updates — ask how the vendor notifies institutions of updates that touch validated functionality, and what re-validation the institution is expected to perform after each release.

Institutions running FDA-regulated trials should involve their own quality/regulatory affairs function in this part of the evaluation rather than treating it as purely an IT or research-office decision — validation adequacy is a compliance determination, not a technical one.

Cost Structure

CTMS pricing is generally negotiated per institution and not published, so this guide will not assert specific dollar figures — ask each vendor directly for current pricing and get it in writing before comparing options. What buyers can evaluate without vendor-specific numbers is the structure of the cost, which varies meaningfully across the market:

Licensing model: per-user/per-seat, per-study, per-site, or enterprise/site-wide licensing — each scales differently as trial volume grows, so model your actual (not current) trial volume against each pricing structure before comparing quotes.
Implementation and configuration costs, often a substantial one-time cost separate from ongoing licensing, particularly for enterprise platforms requiring significant configuration to match institutional workflows.
Integration and interface costs for connecting to EDC, eTMF, RTSM, the EHR, or a grants/financial system — frequently quoted separately from the base platform and easy to underestimate during initial budgeting.
Ongoing support, hosting, and upgrade costs, and whether validation-support services (see above) are included or billed separately.
Training costs for initial rollout and for onboarding new staff on an ongoing basis, which recurs for the life of the system and is easy to omit from a first-year budget.

Building a multi-year total cost of ownership model — not just first-year licensing — is the single most effective way to compare cost structures fairly across vendors quoting different pricing models. See The Cost of Running a Clinical Trial for how CTMS and other operational costs fit into overall trial budgeting.

Major Platform Categories

The commercial CTMS market spans a few broad categories. This is a category overview, not a product recommendation or a pricing comparison — feature sets and market positioning change, and any institution should confirm current capabilities directly with vendors during its own evaluation.

Academic medical center-oriented enterprise platforms. OnCore, developed by Advarra (the platform originated with Forte Research Systems, which Advarra acquired), is widely used across US academic medical centers and cancer centers, with configuration built around institutional research-office workflows, IRB integration, and research billing compliance. WCG’s Velos eResearch (the CTMS line WCG acquired from Velos in 2019, offered in both a full “Enterprise” configuration and a lighter “eXpress” configuration aimed at smaller institutions) occupies similar territory. These platforms are generally deployed institution-wide across a research office rather than licensed per trial.
Sponsor/CRO-grade enterprise platforms. Medidata Rave CTMS and Veeva Vault CTMS are examples of CTMS offerings built primarily for pharmaceutical sponsors and CROs managing large multi-site, multi-country trial portfolios, often as part of a broader unified clinical cloud/vault suite alongside EDC and eTMF from the same vendor. These are less commonly the primary system for a single academic research office, though a site participating in an industry-sponsored trial may be required to use a sponsor’s chosen system alongside its own institutional CTMS.
Lighter-weight and single-site options. Smaller or newer research programs sometimes start with narrower tools — a study-tracking module bolted onto an existing EDC deployment, or, for investigator-initiated and lower-risk studies, a general-purpose research data platform like REDCap used for lightweight subject tracking rather than a purpose-built CTMS. This can be a reasonable starting point for a low-volume program, but it typically lacks the financial-tracking, multi-study reporting, and validation documentation an enterprise CTMS provides as trial volume grows — treat it as a starting point to outgrow, not a permanent substitute, once portfolio volume or regulatory scope increases.

Vendor names and market positioning here reflect the state of the market at the time of writing and are provided as category examples, not an endorsement or an exhaustive vendor list — run a current market scan (e.g., via peer institutions, professional associations, or an RFP) as part of any real procurement process rather than relying on any single guide.

A Practical Selection Process

Convene stakeholders early. A CTMS selection touches the research office, IRB/regulatory affairs, research finance/billing compliance, IT/information security, and clinical departments. Missing a stakeholder group (research billing is the most commonly under-represented one) tends to surface as a painful gap after implementation rather than during selection.
Document current-state workflows and pain points before writing requirements, so the RFP reflects actual institutional needs rather than a generic feature checklist copied from a vendor’s own marketing material.
Score against the criteria above — core functionality, integration, deployment model, validation support, and cost structure — using a weighted scorecard so the final decision is traceable back to institutional priorities, not just which demo was most polished.
Request a hands-on evaluation or pilot, not just a scripted demo, using real (or realistic de-identified) institutional data and workflows, including at least one financial/billing scenario and one regulatory-document scenario.
Check references at peer institutions of comparable size and trial portfolio, specifically about implementation timeline, ongoing support responsiveness, and how the vendor has handled validation and Part 11 questions in practice.
Plan the validation and migration path before signing — who validates the system (vendor-supplied IQ/OQ package vs. institution-performed), and how existing data from a prior CTMS or from spreadsheets/shadow systems will be migrated and verified for accuracy.

Common Pitfalls

Evaluating only the research-office workflow and treating financial/billing-compliance functionality as a lower priority, then discovering post-implementation that Medicare Coverage Analysis and sponsor invoicing don’t fit the configured system well.
Underestimating implementation and configuration timelines. Enterprise CTMS implementations at multi-site institutions commonly take many months from contract signature to go-live once configuration, integration, validation, and staff training are accounted for — build this into any transition plan rather than assuming a rapid cutover.
Treating validation as a one-time event rather than an ongoing obligation that recurs with vendor updates.
Sizing for current volume only, without modeling how licensing costs and configuration limits behave as the trial portfolio grows.
Skipping reference checks with genuinely comparable institutions — a vendor reference list skewed toward very large or very small institutions relative to your own can mask fit problems that only show up at your actual scale.

Frequently Asked Questions

Is a CTMS legally required for running clinical trials?

No single regulation mandates use of a specific CTMS product. What regulations and institutional policy do require — accurate subject tracking, essential document retention, audit trails, and (where applicable) 21 CFR Part 11-compliant electronic records — is, in practice, difficult to demonstrate reliably at any real scale without one. See Clinical Trial Management System (CTMS): What It Is and Does for more on this distinction.

What is the difference between a CTMS and an EDC system, for selection purposes?

EDC captures and manages clinical trial data (case report form entries); CTMS manages trial operations (subjects, visits, budgets, regulatory documents). Many institutions run both and integrate them rather than relying on either alone. See Clinical Data Management Tools for the full landscape.

Can REDCap substitute for a full CTMS?

For low-volume or single-study use, some programs use REDCap for basic subject tracking. It generally isn’t a substitute for the financial-tracking, multi-study institutional reporting, and validation documentation a purpose-built CTMS provides once a portfolio grows past a small number of studies. See REDCap.

How long does a CTMS implementation typically take?

Timelines vary substantially by institution size, degree of configuration, and integration scope, but enterprise multi-site implementations commonly run to many months from contract to go-live once configuration, data migration, validation, and staff training are included. Build the timeline into the procurement schedule, not just the technical rollout plan.

Does a cloud-hosted CTMS still need to be validated?

Yes. Deployment model (cloud vs. on-premise) does not change the institution’s underlying obligation to demonstrate the system reliably supports the records and signatures it produces. What changes is who performs which part of that work — a cloud vendor may supply a validation package the institution reviews and adopts, rather than the institution performing full infrastructure-level validation itself, but the institution remains accountable for confirming that work is adequate.

How to Select a Clinical Trial Management System (CTMS): A Buyer’s Guide